Tris(2-chloroethyl) phosphate


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:22446829IVTH0.01 - 10 mg/L 10 mg/LAffects steroidogenesisReproductive endocrine-mediated perturbations
IVTH0.01 - 10 mg/L 0.1 - 10 mg/LIncreased estradiol levelsReproductive endocrine-mediated perturbations
IVTH0.01 - 10 mg/L 0.1 - 10 mg/LIncreased testosterone levelsReproductive endocrine-mediated perturbations
PMID:26183808IVR300 mg/kg 300 mg/kgAffects the biochemical composition of liverHepatic endocrine-mediated perturbations
IVR300 mg/kg 300 mg/kgDecreased testis weightsReproductive endocrine-mediated perturbations
IVR300 mg/kg 300 mg/kgAffects steroidogenesisReproductive endocrine-mediated perturbations
IVR100 mg/kg 100 mg/kgAffects the biochemical composition of liverHepatic endocrine-mediated perturbations
PMID:8314462IVR44 mg/kg 44 mg/kgHematopietic carcinomaEndocrine-mediated cancer;Immunological endocrine-mediated perturbations
IVR88 mg/kg 88 mg/kgHematopietic carcinomaEndocrine-mediated cancer;Immunological endocrine-mediated perturbations
IVR88 mg/kg 88 mg/kgChanges in brain morphologyNeurological endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.